SEARCH

SEARCH BY CITATION

References

  • 1
    Schröder H, Campbell DES. Absorption, metabolism and excretion of salicylazusulfapyridine in man. Clin Pharmacol Ther 1972; 13: 53951.
  • 2
    Brogden RN, Sorkin EM. Mesalazine (5-ASA). An overview of its clinical pharmacological properties and therapeutic potential in inflammatory bowel disease. Drugs 1989; 38: 50023.
  • 3
    Schwab S, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 2001; 40(10): 72351.
  • 4
    Shanahan F. Crohn's disease. Lancet 2002; 359: 629.
  • 5
    Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet 2002; 359: 33140.
  • 6
    Greenfield SM, Punchard NA, Teare JP, et al. The mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 1993; 7: 36983.
  • 7
    Mutschler E, Geisslinger G, Kroemer HK, Schaefer-Korting M. Arzneimittelwirkungen, 8. Auflage. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 2001: 6457.
  • 8
    Ireland A, Jewell DP. Mechanism of action of 5-aminosalicylic acid and its derivates. Clin Sci (Colch) 1990; 78: 11925.
  • 9
    Allgayer H, Ahnfelt NO, Kruis W, et al. Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology 1989; 97: 3841.
  • 10
    Zhou SY, Fleisher D, Pao LH, et al. Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab Dispos 1999; 27: 47989.
  • 11
    Christensen LA, Fallingborg J, Abildgaard K, et al. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. Aliment Pharmacol Ther 1990; 4: 52333.
  • 12
    De Vos M, Verdievel H, Schoonjans R, et al. Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations. Gut 1992; 33: 133842.
  • 13
    Klotz U, Seyffer R, Allgayer H, Maier KE. Pharmacokinetic properties of mesalazine (5-aminosalicylic acid). In: MacDermottRP, ed. Inflammatory Bowel Disease: Current Status and Future Approach. Amsterdam: Elsevier Science Publishers B.V. (Biomedical Division), 1988: 7259.
  • 14
    Tromm A, Griga T, May B. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties. Hepatogastroenterology 1999; 46: 312435.
  • 15
    Clemett D, Markham A. Prolonged-release mesalazine. A review of its therapeutic potential in ulcerative colitis and Crohn's disease. Drugs 2000; 59: 92956.
  • 16
    Frieri G, Pimpo MT, Andreoli A, et al. Prevention of post-operative recurrence of Crohn's disease requires adequate mucosal concentration of mesalazine. Aliment Pharmacol Ther 1999; 13: 57782.
  • 17
    Frieri G, Giacomelli R, Pimpo M, Palumbo G, Passacantando A, Caprilli R. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut 2000; 47: 4104.
  • 18
    Layer PH, Goebell H, Keller J, Gignass A, Klotz U. Delivery and fate of oral mesalamine mircogranules within the human small intestine. Gastroenterology 1995; 108: 142733.
  • 19
    Bondesen S, Bronnum-Schon J, Pedersen V, Rafiolsadat Z, Honore Hansen S, Huidberg EF. Absorption of 5-aminosalicylic acid from colon and rectum. Br J Pharmacol 1988; 25: 26972.
  • 20
    Myers B, Evans DNW, Rhodes J, et al. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 1987; 28(2): 196200.
  • 21
    Gisbert JP, Gomollon F, Maté J, Pajares JM. Role of 5-aminosalicylic acid in treatment of inflammatory bowel disease: a systematic review. Digestive Dis Sci 2002; 3: 47188.
  • 22
    Hardy JG, Healey JNC, Reynolds JR. Evaluations of an enteric coated delayed release 5-ASA tablet in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1987; 1: 27389.
  • 23
    Dew MJ, Ebden P, Kidwai NS, et al. Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-aminosalicylic acid in normal subjects and patients with colitis. Br J Clin Pharmacol 1984; 17: 4746.
  • 24
    Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 16259.
  • 25
    Shah VP, Midha KK, Dighe S, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. J Pharm Sci 1992; 81(3): 30912.
  • 26
    Evans DF, Pye G, Bramley R, Clarke AG, Dyson TJ, Hardcastle JB. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 1988; 29: 103541.
  • 27
    Fallingborg J, Christensen LA, Ingeman-Nielsen M, et al. pH-Profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther 1989; 3: 60513.
  • 28
    Leopold CS. Coated dosage forms for colon-specific drug delivery. Pharmaceut Sci Technol Today 1999; 2: 197204.
  • 29
    Nick C. Formulations on trial. Good Clinical Practice 1996; 3(5): 206.
  • 30
    Meseguer G, Gurny R, Buri P. In vivo behaviour of dosage forms: application of gamma scintigraphy to non-enteral routes of administration. J Drug Targeting 1994; 2: 26988.
  • 31
    Coupe AJ, Davis SS, Wilding IR. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res 1991; 8: 3604.
  • 32
    De Vos M, Verdievel HR, Schoonjans Praet M, Bogaert M, Barbier F. Concentrations of 5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations. Gut 1992; 33: 133842.
  • 33
    Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut 1986; 27: 88692.
  • 34
    Wilding IR. Bioequivalence testing for locally acting gastrointestinal products: what role for gamma scintigraphy? J Clin Pharm 2002; 42: 120010.
  • 35
    The European Agency for Evaluation of Medical Products. CPMP/ENP/239/95 Final Note for Guidance on the Clinical Requirements for Locally Applied, Locally Acting Products Containing Known Constituents. London: Human Medicine Evaluation Unit, in operation from June 1996.